{"id":"group-c-chlorthalidone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hyponatremia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108795","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Chlorthalidone blocks the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, preventing electrolyte reabsorption and increasing urine output. This reduces circulating blood volume and total peripheral resistance, leading to decreased blood pressure. It also has mild vasodilatory properties that contribute to its antihypertensive effect.","oneSentence":"Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, promoting urinary excretion and reducing blood volume and blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:31.758Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Edema associated with congestive heart failure or renal disease"}]},"trialDetails":[{"nctId":"NCT02847338","phase":"PHASE4","title":"Comparison of Optimal Hypertension Regimens","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2016-11","conditions":"Hypertension","enrollment":940},{"nctId":"NCT03006796","phase":"","title":"Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.","status":"COMPLETED","sponsor":"Russian Heart Failure Society","startDate":"2017-01-16","conditions":"Arterial Hypertension","enrollment":94},{"nctId":"NCT01850160","phase":"PHASE3","title":"Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension","status":"COMPLETED","sponsor":"Farma de Colombia SA","startDate":"2013-04","conditions":"Hypertension","enrollment":124}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sodium Chloride Symporter Inhibitors","Antihypertensive Agents","Diuretics"],"phase":"phase_3","status":"active","brandName":"GROUP C: Chlorthalidone","genericName":"GROUP C: Chlorthalidone","companyName":"Farma de Colombia SA","companyId":"farma-de-colombia-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chlorthalidone is used to treat hypertension and arterial hypertension. It is often used in combination with other medications, such as valsartan, but can also be used as a standalone treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}